Calcium Pyrophosphate Deposition (CPPD) Disease
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorLille Catholic University
About this trial
The goal of this clinical trial is to describe the transcriptomic and metabolomic profile of patients with chronic Calcium Pyrophosphate Deposition (CPPD) compared to those with acute CPPD.
The hypotheses are as follows :
* It is hypothesised that there is a transcriptomic and metabolomic signature of CPPD which explains why therapeutic responses to different anti-inflammatory treatments differ from one phenotype to another one * It is hypothesised that the acute and chronic clinical phenotypes of CPPD have different clinical, biological and imaging characteristics, as well as a differing predisposition toward crystalline deposition and inflammatory pathway activation.
The management of participants with chronic forms of the disease included in this research was modelled on the usual recommended management, including a biological workup, joint puncture, ultrasound and radiographic workup. Double-energy CT scans and transcriptomic and metabolomic analyses on plasma are not routine tests.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Acute forms of CPPD: retrospective part of the study
Cases included in the COLCHICORT cohort (NCT03128905), for whom this was the first acute episode of CPPD
Patients affiliated to the French social security system
Age ≥ 65 years
Disqualifiers
Missing data concerning transcriptomic and metabolomic analyses.
Opposition
History of gout or presence of monosodium urate (MSU) crystals on joint fluid,
Cognitive decline (confusion and neurodegenerative diseases)
Trial design
Design model
Single group
Treatments tested in this trial
transcriptomic and metabolomic analysis
GeneticVenous blood samples for transcriptomic and metabolomic analysis will be taken in 3 x 4 mL ethylenediaminetetraacetic acid (EDTA) tubes and stored immediately at 4°C, before being cryopreserved at -80°C in 500 μL aliquots of plasma. In addition, for transcriptomic analysis, a sample will also be taken in a Paxgen RNA tube cryopreserved at -80°C.
Treatment groups
137 Participants
are divided into 1 treatment groupGroup A: Patients with a chronic CPPDExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Transcriptomic profile
-Quantitative transcriptomic profiling (expression of the genes involved) and qualitative profiling (analysis of the sequence of variants expressed)
Time frame
2 weeks2
Metabolomic profile
\- Metabolomic profile: quantitative assessment of the metabolites involved in each phenotype, then qualitatively grouped by activated metabolic pathway
Time frame
2 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: